Lillys phase 3 ATTAIN-1 results, later published in The New England Journal of Medicine via PubMed, reported average weight loss of 12.4% at the highest dose over 72 weeks in adults with obesity or overweight without type 2 diabetes
The SURMOUNT-4 trial showed even steeper rebounds with tirzepatide, with participants regaining more than 50% of their weight loss over 52 weeks after stopping
I was lucky enough to be in the advisory committee meeting where the substance that makes up Ozempic and Wegovy was discussed before it was approved, she says
PMID 33617860 Elamipretide (SS-31): +3 charge, mitochondrial cardiolipin accumulation, and injection-site-reaction profile (review)
If you purchase an independently reviewed product or service through a link on our website, The Hollywood Reporter may receive an affiliate commission
Two neurons mediate diet-restriction-induced longevity in C